Sarepta Therapeutics Ownership
| SRPT Stock | USD 14.08 7.89 35.91% |
Shares in Circulation | First Issued 1996-03-31 | Previous Quarter 108.5 M | Current Value 97.4 M | Avarage Shares Outstanding 33.4 M | Quarterly Volatility 32.8 M |
Sarepta Stock Ownership Analysis
About 96.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.89. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Sarepta Therapeutics recorded a loss per share of 2.64. The entity had not issued any dividends in recent years. The firm had 1:6 split on the 12th of July 2012. Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. Sarepta Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 840 people. To find out more about Sarepta Therapeutics contact Douglas Esq at 617 274 4000 or learn more at https://www.sarepta.com.Besides selling stocks to institutional investors, Sarepta Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Sarepta Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Sarepta Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Sarepta Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Sarepta Therapeutics Insider Trades History
About 4.0% of Sarepta Therapeutics are currently held by insiders. Unlike Sarepta Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Sarepta Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Sarepta Therapeutics' insider trades
Sarepta Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Sarepta Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Sarepta Therapeutics backward and forwards among themselves. Sarepta Therapeutics' institutional investor refers to the entity that pools money to purchase Sarepta Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2025-03-31 | 1.8 M | Deutsche Bank Ag | 2025-03-31 | 1.7 M | Ubs Group Ag | 2025-03-31 | 1.4 M | Groupama Asset Management | 2025-03-31 | 1.3 M | Ecor1 Capital, Llc | 2025-03-31 | 1.3 M | Erste Asset Management Gmbh | 2025-03-31 | 1.1 M | Norges Bank | 2024-12-31 | 1 M | Pictet Asset Manangement Sa | 2025-03-31 | 937 K | Casdin Capital, Llc | 2025-03-31 | 900.8 K | Blackrock Inc | 2025-03-31 | 9.9 M | Capital Research & Mgmt Co - Division 3 | 2025-03-31 | 9.1 M |
Sarepta Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Sarepta Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Sarepta Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Sarepta Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Sarepta Therapeutics Outstanding Bonds
Sarepta Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Sarepta Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Sarepta bonds can be classified according to their maturity, which is the date when Sarepta Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Sarepta Therapeutics Corporate Filings
8K | 16th of July 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 19th of May 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 6th of May 2025 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
| 24th of April 2025 Other Reports | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Sarepta Stock Analysis
When running Sarepta Therapeutics' price analysis, check to measure Sarepta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sarepta Therapeutics is operating at the current time. Most of Sarepta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sarepta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sarepta Therapeutics' price. Additionally, you may evaluate how the addition of Sarepta Therapeutics to your portfolios can decrease your overall portfolio volatility.